SEHK:2696Biotechs
Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?
HLX43 and HLX3902 milestones put Shanghai Henlius Biotech’s pipeline in focus
Shanghai Henlius Biotech (SEHK:2696) has reported fresh progress in its oncology pipeline. Regulators in China cleared a new HLX43 clinical trial in advanced solid tumours, and the first patient received HLX3902 in an early prostate cancer study.
See our latest analysis for Shanghai Henlius Biotech.
Shanghai Henlius Biotech’s recent HLX43 and HLX3902 updates have arrived alongside a sharp shift in sentiment, with...